Preclinical efficacy of the oncolytic measles virus expressing the sodium iodide symporter in iodine non-avid anaplastic thyroid cancer: A novel therapeutic agent allowing noninvasive imaging and radioiodine therapy

Cancer Gene Therapy

Volumn 19, Issue 9, 2012, Pages 659-665

  Reddi, H V ^a   Madde, P ^a   McDonough, S J ^a   Trujillo, M A ^a   Morris, J C ^a   Myers, R M ^a   Peng, K W ^a   Russell, S J ^a   McIver, B ^a   Eberhardt, N L ^a  

^a MAYO CLINIC   (United States)

Author keywords

anaplastic thyroid carcinoma; MV NIS; novel therapeutic agent; sodium iodide symporter dysfunction

Indexed keywords

IODINE 131; MEMBRANE COFACTOR PROTEIN; ONCOLYTIC VIRUS; ONCOLYTIC VIRUS SODIUM IODIDE SYMPORTER; SODIUM IODIDE SYMPORTER; TECHNETIUM 99M; UNCLASSIFIED DRUG;

ANAPLASTIC THYROID CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER PROGNOSIS; CONTROLLED STUDY; DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN TISSUE; MOUSE; MYELOMA; NON INVASIVE MEASUREMENT; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR CELL; WESTERN BLOTTING;

MEASLES VIRUS;

EID: 84865266991     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2012.47     Document Type: Article

References (43)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212-236.
2. Farahati J, Geling M, Mader U, Mortl M, Luster M, Muller JG et al. Changing trends of incidence and prognosis of thyroid carcinoma in lower Franconia, Germany, from 1981-1995. Thyroid 2004; 14: 141-147.
3. Haigh PI. Anaplastic thyroid carcinoma. Curr Treat Options Oncol 2000; 1: 353-357.
4. Are C, Shaha AR. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol 2006; 13: 453-464.
5. Foote RL, Molina JR, Kasperbauer JL, Lloyd RV, McIver B, Morris JC et al. Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a singleinstitution experience using aggressive multimodal therapy. Thyroid 2011; 21: 25-30.
6. Kim JE, Ahn BC, Hwang MH, Jeon YH, Jeong SY, Lee SW et al. Combined RNA interference of hexokinase II and (131)I-sodium iodide symporter gene therapy for anaplastic thyroid carcinoma. J Nucl Med 2011; 52: 1756-1763.
7. Libertini S, Abagnale A, Passaro C, Botta G, Barbato S, Chieffi P et al. AZD1152 negatively affects the growth of anaplastic thyroid carcinoma cells and enhances the effects of oncolytic virus dl922-947. Endocr Relat Cancer 2011; 18: 129-141.
8. Libertini S, Iacuzzo I, Perruolo G, Scala S, Ierano C, Franco R et al. Bevacizumab increases viral distribution in human anaplastic thyroid carcinoma xenografts and enhances the effects of E1A-defective adenovirus dl922-947. Clin Cancer Res 2008; 14: 6505-6514.
9. Reddi HV, Madde P, Reichert-Eberhardt AJ, Galanis EC, Copland JA, McIver B et al. ONYX-411, a conditionally replicative oncolytic adenovirus, induces cell death in anaplastic thyroid carcinoma cell lines and suppresses the growth of xenograft tumors in nude mice. Cancer Gene Ther 2008; 15: 750-757.
10. Lin SF, Gao SP, Price DL, Li S, Chou TC, Singh P et al. Synergy of a herpes oncolytic virus and paclitaxel for anaplastic thyroid cancer. Clin Cancer Res 2008; 14: 1519-1528.
11. Lin SF, Yu Z, Riedl C, Woo Y, Zhang Q, Yu YA et al. Treatment of anaplastic thyroid carcinoma in vitro with a mutant vaccinia virus. Surgery 2007; 142: 976-983; discussion 976-983.
12. Lin SF, Price DL, Chen CH, Brader P, Li S, Gonzalez L et al. Oncolytic vaccinia virotherapy of anaplastic thyroid cancer in vivo. J Clin Endocrinol Metab 2008; 93: 4403-4407.
13. Kim KI, Kang JH, Chung JK, Lee YJ, Jeong JM, Lee DS et al. Doxorubicin enhances the expression of transgene under control of the CMV promoter in anaplastic thyroid carcinoma cells. J Nucl Med 2007; 48: 1553-1561.
14. Libertini S, Iacuzzo I, Ferraro A, Vitale M, Bifulco M, Fusco A et al. Lovastatin enhances the replication of the oncolytic adenovirus dl1520 and its antineoplastic activity against anaplastic thyroid carcinoma cells. Endocrinology 2007; 148: 5186-5194.
15. Huang YY, Yu Z, Lin SF, Li S, Fong Y, Wong RJ. Nectin-1 is a marker of thyroid cancer sensitivity to herpes oncolytic therapy. J Clin Endocrinol Metab 2007; 92: 1965-1970.
16. Abbosh PH, Li X, Li L, Gardner TA, Kao C, Nephew KP. A conditionally replicative, Wnt/beta-catenin pathway-based adenovirus therapy for anaplastic thyroid cancer. Cancer Gene Ther 2007; 14: 399-408.
17. Yu Z, Eisenberg DP, Singh B, Shah JP, Fong Y, Wong RJ. Treatment of aggressive thyroid cancer with an oncolytic herpes virus. Int J Cancer 2004; 112: 525-532.
18. Portella G, Pacelli R, Libertini S, Cella L, Vecchio G, Salvatore M et al. ONYX-015 enhances radiation-induced death of human anaplastic thyroid carcinoma cells. J Clin Endocrinol Metab 2003; 88: 5027-5032.
19. Portella G, Scala S, Vitagliano D, Vecchio G, Fusco A. ONYX-015, an E1B gene-defective adenovirus, induces cell death in human anaplastic thyroid carcinoma cell lines. J Clin Endocrinol Metab 2002; 87: 2525-2531.
20. Mullen JT, Tanabe KK. Viral oncolysis. Oncol 2002; 7: 106-119.
21. Smallridge RC, Copland JA. Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. Clin Oncol (Royal College of Radiologists (Great Britain)) 2010; 22: 486-497.
22. Smallridge RC, Marlow LA, Copland JA. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer 2009; 16: 17-44.
23. Hasegawa K, Nakamura T, Harvey M, Ikeda Y, Oberg A, Figini M et al. The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer. Clin Cancer Res 2006; 12(20 Part 1): 6170-6178.
24. Dingli D, Peng KW, Harvey ME, Greipp PR, O'Connor MK, Cattaneo R et al. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 2004; 103: 1641-1646.
25. Cho CH, Nuttall ME. Emerging techniques for the discovery and validation of therapeutic targets for skeletal diseases. Expert Opin Ther Targets 2002; 6: 679-689.
26. Van Nostrand D, Wartofsky L. Radioiodine in the treatment of thyroid cancer. Endocrinol Metab Clin North Am 2007; 36: 807-822, vii-viii.
27. Hasegawa K, Pham L, O'Connor MK, Federspiel MJ, Russell SJ, Peng KW. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter. Clin Cancer Res 2006; 12: 1868-1875.
28. Blechacz B, Splinter PL, Greiner S, Myers R, Peng KW, Federspiel MJ et al. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma. Hepatology (Baltimore, MD) 2006; 44: 1465-1477.
29. Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA et al. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentifica-tion. J Clin Endocrinol Metab 2008; 93: 4331-4341.
30. Castro MR, Bergert ER, Beito TG, McIver B, Goellner JR, Morris JC. Development of monoclonal antibodies against the human sodium iodide symporter: immuno-histochemical characterization of this protein in thyroid cells. J Clin Endocrinol Metab 1999; 84: 2957-2962.
31. Denizot F, Lang R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Meth 1986; 89: 271-277.
32. Spitzweg C, Dietz AB, O'Connor MK, Bergert ER, Tindall DJ, Young CY et al. In vivo sodium iodide symporter gene therapy of prostate cancer. Gene Ther 2001; 8: 1524-1531.
33. Smit JW, Schroder-van der Elst JP, Karperien M, Que I, Stokkel M, van der Heide D et al. Iodide kinetics and experimental (131)I therapy in a xenotransplanted human sodium-iodide symporter-transfected human follicular thyroid carcinoma cell line. J Clin Endocrinol Metab 2002; 87: 1247-1253.
34. Ain KB. Management of undifferentiated thyroid cancer. Baillieres Best Pract Res Clin Endocrinol Metab 2000; 14: 615-629.
35. Dhiman N, Jacobson RM, Poland GA. Measles virus receptors: SLAM and CD46. Rev Med Virol 2004; 14: 217-229.
36. Yamakawa M, Yamada K, Tsuge T, Ohrui H, Ogata T, Dobashi M et al. Protection of thyroid cancer cells by complement-regulatory factors. Cancer 1994; 73: 2808-2817.
37. Li H, Peng KW, Russell SJ. Oncolytic measles virus encoding thyroidal sodium iodide symporter for squamous cell cancer of the head and neck radio-virotherapy. Hum Gene Ther 2012; 23: 295-301.
38. Opyrchal M, Allen C, Iankov I, Aderca I, Schroeder M, Sarkaria J, et al. Effective radiovirotherapy for malignant gliomas by using oncolytic measles virus strains encoding the sodium iodide symporter (MV-NIS). Hum Gene Ther 2012; 23: 419-427.
39. Msaouel P, Iankov ID, Allen C, Aderca I, Federspiel MJ, Tindall DJ et al. Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter. Mol Ther 2009; 17: 2041-2048.
40. Penheiter AR, Wegman TR, Classic KL, Dingli D, Bender CE, Russell SJ et al. Sodium iodide symporter (NIS)-mediated radiovirotherapy for pancreatic cancer. Am J Roentgenol 2010; 195: 341-349.
41. Namba H, Hara T, Tukazaki T, Migita K, Ishikawa N, Ito K et al. Radiation-induced G1 arrest is selectively mediated by the p53-WAF1/Cip1 pathway in human thyroid cells. Cancer Res 1995; 55: 2075-2080.
42. Yang T, Namba H, Hara T, Takmura N, Nagayama Y, Fukata S et al. p53 induced by ionizing radiation mediates DNA end-jointing activity, but not apoptosis of thyroid cells. Oncogene 1997; 14: 1511-1519.
43. Bulgin D, Podtcheko A, Takakura S, Mitsutake N, Namba H, Saenko V et al. Selective pharmacologic inhibition of c-Jun NH2-terminal kinase radiosensitizes thyroid anaplastic cancer cell lines via induction of terminal growth arrest. Thyroid 2006; 16: 217-224.